ARK Investment Management LLC has recently announced that it has increased stake in Intellia Therapeutics Inc. (NASDAQ:NTLA) by 4.42%. After grabbing 9.84 million shares, the institutional investor is now in possession of 0.42 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 11.18% having worth around $371.35 million. Moreover, The Vanguard Group, Inc. increased its share by 0.32 million to have a control over 7.94 million shares. And Nikko Asset Management Americas, raised its holdings to 0.14 million shares by acquiring 3.11 million shares or 3.54% of the stake.
Intellia Therapeutics Inc. (NTLA) concluded trading on 05/25/23 at a closing price of $39.22, with 1.18 million shares of worth about $46.12 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.81% during that period and on Thursday the price saw a loss of about -6.08%. Currently the company’s common shares owned by public are about 87.77M shares, out of which, 75.75M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 30 analysts are covering the NTLA stock and their offered price forecasts bring an average price target of $89.92. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $154.00 and could fall to a lowest price of $44.00. The stock’s current price level is 57.07% above of average price target set by the analysts, while a rise to estimated low would result in gain of 10.86% for the stock. However, touching the estimated high of $154.00 would mean a gain of 74.53% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 34 times over the past 12 months. They bought 336,644 shares in 22 of the transactions. In 12 selling transactions, insiders dumped 22,578 shares.
ARK Innovation ETF, Vanguard Total Stock Market ETF, and Nikko AM Global Umbrella Fund – A are the top 3 mutual funds which are holding stakes in Intellia Therapeutics Inc. ARK Innovation ETF is currently holding 6.78 million shares of worth totaling $256.07 million. The company recently came buying 10920.0 shares which brought its stake up to 7.71% of the company’s outstanding shares. Vanguard Total Stock Market ETF bought 1347.0 shares, after which its hold over company’s outstanding shares expand to 2.97%, leaving 2.62 million shares with the mutual fund that have a worth of about $98.76 million. Nikko AM Global Umbrella Fund – A, after buying 2.36 million shares, have now control over 2.68% of the stake in the company. It holds 52226.0 shares of worth $89.11 million.
Intellia Therapeutics Inc. (NASDAQ: NTLA) started trading at $41.65, below -$0.11 from concluding price of the previous day. However, the stock later moved at a day high price of 41.65, or with a loss of -6.08%. Stock saw a price change of -8.71% in past 5 days and over the past one month there was a price change of 8.25%. Year-to-date (YTD), NTLA shares are showing a performance of 12.41% which decreased to -8.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $32.44 but also hit the highest price of $76.45 during that period. The average intraday trading volume for Intellia Therapeutics Inc. shares is 1.11 million. The stock is currently trading -6.96% below its 20-day simple moving average (SMA20), while that difference is down -0.09% for SMA50 and it goes to -14.73% lower than SMA200.
ARK Investment Management LLC acquired 9.84 million shares of Intellia Therapeutics Inc. having value of about $371.35 million. Data submitted at the U.S SEC by ARK Investment Management LLC revealed that the firm now holds 0.42 million shares in the company valued at close to $16330580.48, or have control over 4.42% stake in the company. Intellia Therapeutics Inc. (NASDAQ: NTLA) currently have 87.77M outstanding shares and institutions hold larger chunk of about 80.40% of that. Holding of mutual funds in the company is about 33.23% while other institutional holders and individual stake holders have control over 52.60% and 19.48% of the stake respectively.
The stock has a current market capitalization of $3.53B and its 3Y-monthly beta is at 1.81. It has posted earnings per share of -$5.39 in the same period. It has Quick Ratio of 9.30 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 5.67% while standing at 5.47% over the month.
Analysts are in expectations that Intellia Therapeutics Inc. (NTLA) stock would likely to be making an EPS of -$1.33 in the current quarter, while forecast for next quarter EPS is -$1.39 and it is -$5.78 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.59 which is -$1.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.33 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -63.00% while it is estimated to decrease by -7.20% in next year. EPS is likely to grow at an annualized rate of 30.00% for next 5-years, compared to annual growth of -26.80% made by the stock over the past 5-years.
Analysts at 30 brokerage firms have issued recommendations for the Intellia Therapeutics Inc. (NTLA)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.90. Out of those 30 Wall Street analysts, 22 recommended a “Buy” rating, while 4 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Leave a Reply